{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05886920",
            "orgStudyIdInfo": {
                "id": "D3S-002-100"
            },
            "organization": {
                "fullName": "D3 Bio (Wuxi) Co., Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations",
            "officialTitle": "A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-as-monotherapy-in-adult-subjects-with-advanced-solid-tumors-with-mapk-pathway-mutations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-24",
            "studyFirstSubmitQcDate": "2023-05-24",
            "studyFirstPostDateStruct": {
                "date": "2023-06-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "D3 Bio (Wuxi) Co., Ltd",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumors With MAPK Pathway Mutations"
            ],
            "keywords": [
                "Advanced solid tumors",
                "mitogen-activated protein kinase",
                "mutation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "D3S-002",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Escalation, D3S-002 administered orally.",
                    "interventionNames": [
                        "Drug: D3S-002"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "D3S-002",
                    "description": "Oral",
                    "armGroupLabels": [
                        "D3S-002"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants With Adverse Events (AEs)",
                    "timeFrame": "First dose until 30 days after the last dose (or specified in the protocol)"
                },
                {
                    "measure": "Number of Participants With Dose-Limiting Toxicities (DLTs)",
                    "timeFrame": "From Cycle 1 Day 1 through Day 21. Each cycle is 21 days."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "D3S-002 maximum observed plasma concentration (Cmax)",
                    "timeFrame": "First dose up to 24 months"
                },
                {
                    "measure": "D3S-002 time to maximum plasma concentration (tmax)",
                    "timeFrame": "First dose up to 24 months"
                },
                {
                    "measure": "D3S-002 half-life (t1/2)",
                    "timeFrame": "First dose up to 24 months"
                },
                {
                    "measure": "D3S-002 area under the concentration-time curve (AUC)",
                    "timeFrame": "First dose up to 24 months"
                },
                {
                    "measure": "Objective response rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
                    "timeFrame": "Until disease progression or end of treatment (up to approximately 24 months)"
                },
                {
                    "measure": "Disease control rate (DCR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
                    "timeFrame": "Until disease progression or end of treatment (up to approximately 24 months)"
                },
                {
                    "measure": "Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
                    "timeFrame": "Until disease progression or end of treatment (up to approximately 24 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion:\n\n* Subjects must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor with evidence of progressive disease.\n* Subjects must have documented mitogen-activated protein kinase (MAPK) pathway mutation(s) within the last 5 years identified by a local test on tumor tissue or blood (eg, rat sarcoma (RAS), rapidly accelerated fibrosarcoma (RAF), and MAPK kinase (MAPKK) mutations).\n* Subjects must be refractory to or intolerable with standard treatment, or have no available standard of care.\n* Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Subject must have adequate organ and marrow function within the screening period.\n\nExclusion:\n\n* Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.\n* Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.\n* Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade \u22652 (with exception of vitiligo or alopecia).\n* Subject has active gastrointestinal disease or other that could interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.\n* Any concurrent chemotherapy, immunotherapy, targeted therapy, cell therapy, biologic or hormonal therapy and any medical devices for cancer treatment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Medical Director",
                    "role": "CONTACT",
                    "phone": "+86 21 61635900",
                    "email": "D3bio_CT@d3bio.com"
                }
            ],
            "locations": [
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Blacktown",
                    "state": "New South Wales",
                    "zip": "2148",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.76667,
                        "lon": 150.91667
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Bedford Park",
                    "state": "South Australia",
                    "zip": "5042",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -35.03333,
                        "lon": 138.56667
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "state": "Beijing",
                    "zip": "100142",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Guangzhou",
                    "state": "Guangdong",
                    "zip": "510080",
                    "country": "China",
                    "geoPoint": {
                        "lat": 23.11667,
                        "lon": 113.25
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Harbin",
                    "state": "Heilong Jiang",
                    "zip": "150081",
                    "country": "China",
                    "geoPoint": {
                        "lat": 45.75,
                        "lon": 126.65
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Shanghai",
                    "state": "Shanghai",
                    "zip": "201801",
                    "country": "China",
                    "geoPoint": {
                        "lat": 31.22222,
                        "lon": 121.45806
                    }
                },
                {
                    "facility": "D3 Bio Investigative Site",
                    "status": "RECRUITING",
                    "city": "Hangzhou",
                    "state": "Zhejiang",
                    "zip": "310009",
                    "country": "China",
                    "geoPoint": {
                        "lat": 30.29365,
                        "lon": 120.16142
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}